{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:43:48Z","timestamp":1790675028561,"version":"4.1.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are transformational therapies in the treatment of obesity; yet discontinuation rates are high, and patients experience rapid weight regain after stopping treatment. Few scientific publications have reported patients\u2019 experiences of taking GLP-1 RAs in a variety of health contexts outside its use as treatment for type 2 diabetes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To provide insight into the lived experiences of patients taking GLP-1 RAs to inform optimal long-term weight management treatment.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This qualitative study used inductive thematic analysis of semistructured video interviews conducted between July 22 and September 10, 2025, with participants from 15 US states. Participants included adults who were taking or had previously taken GLP-1 RAs for any treatment indication, recruited through ResearchMatch and snowball sampling.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Themes identified through inductive thematic analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 30 participants, 10 self-identified as men, 1 as nonbinary, and 19 as women; their mean (SD) age was 54.0 (8.8) years. A total of 23 participants were using a GLP-1 RA at time of interview, and 7 participants had stopped GLP-1 RA use. Eight key themes were extracted and categorized into 2 overarching domains. The first domain was patient-reported benefits and trade-offs. It comprised the following themes: (1) reduction in food noise, psychological hunger, or appetite; (2) GLP-1 RAs are not a standalone weight loss solution; (3) wide spectrum of adverse effects experienced; and (4) patients prepared to withstand substantial adverse effects and logistical challenges to achieve weight loss. The second domain was social, clinical, and structural context. It comprised the following themes: (5) perceived stigma associated with taking GLP-1 RAs, influenced by primary indication for prescription; (6) information provision and clinical support are essential but highly variable; (7) access challenges and cost can be prohibitive; and (8) value of shared experiences.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this qualitative study of patient experiences with GLP-1 receptor agonists, participants described GLP-1 RA therapy functioning as a facilitator rather than a replacement for lifestyle change, emphasizing the need for behavioral interventions alongside pharmacotherapy to sustain treatment benefits. Quality of care was highly variable; thus, standardized guidelines for patient education and clinical support could improve expectation management around likely adverse effects and long-term management.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.16951","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:30:19Z","timestamp":1780673419000},"page":"e2616951","source":"Crossref","is-referenced-by-count":3,"title":["Patient Experiences With GLP-1 Receptor Agonists"],"prefix":"10.1001","volume":"9","author":[{"given":"Isabella","family":"de Vere Hunt","sequence":"first","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom"},{"name":"Stanford Center for Digital Health, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Ramirez-Posada","sequence":"additional","affiliation":[{"name":"Stanford Center for Digital Health, Department of Medicine, Stanford University, Stanford, California"},{"name":"Department of Dermatology, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Sam","family":"Babu","sequence":"additional","affiliation":[{"name":"Stanford Internal Medicine, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cati","family":"Brown-Johnson","sequence":"additional","affiliation":[{"name":"Evaluation Sciences Unit, Division of Primary Care and Population Health, Department of Medicine, School of Medicine, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Linos","sequence":"additional","affiliation":[{"name":"Stanford Center for Digital Health, Department of Medicine, Stanford University, Stanford, California"},{"name":"Department of Dermatology, School of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Stanford Center for Digital Health, Department of Medicine, Stanford University, Stanford, California"},{"name":"Division of Cardiovascular Medicine and the Cardiovascular Institute, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"10","key":"zoi260477r1","article-title":"Semaglutide for adults living with obesity.","volume":"10","author":"Bracchiglione","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"zoi260477r2","article-title":"Liraglutide for adults living with obesity.","volume":"10","author":"Meza","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi260477r4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults.","author":"Celletti","journal-title":"JAMA"},{"issue":"10","key":"zoi260477r5","article-title":"Tirzepatide for adults living with obesity.","volume":"10","author":"Franco","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"zoi260477r6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction.","volume":"334","author":"Kr\u00fcger","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"zoi260477r7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists.","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"zoi260477r8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"zoi260477r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes.","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi260477r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity.","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi260477r11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/02813432.2025.2477141","article-title":"Patients\u2019 experiences with GLP1-RAs - a systematic review.","volume":"43","author":"Ibsen","year":"2025","journal-title":"Scand J Prim Health Care"},{"issue":"2","key":"zoi260477r12","doi-asserted-by":"publisher","DOI":"10.1111\/hex.70251","article-title":"What are the experiences, views and perceptions of patients, carers and clinicians of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)? a scoping review.","volume":"28","author":"Febrey","year":"2025","journal-title":"Health Expect"},{"issue":"9","key":"zoi260477r13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: a synthesis of recommendations.","volume":"89","author":"O\u2019Brien","year":"2014","journal-title":"Acad Med"},{"issue":"5","key":"zoi260477r14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","article-title":"Purposeful sampling for qualitative data collection and analysis in mixed method implementation research.","volume":"42","author":"Palinkas","year":"2015","journal-title":"Adm Policy Ment Health"},{"issue":"5","key":"zoi260477r15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2929.2006.02467.x","article-title":"Making sense of qualitative data analysis: an introduction with illustrations from DIPEx (personal experiences of health and illness).","volume":"40","author":"Ziebland","year":"2006","journal-title":"Med Educ"},{"issue":"2","key":"zoi260477r17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology.","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"issue":"3","key":"zoi260477r18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1037\/qup0000215","article-title":"Is member checking the gold standard of quality in qualitative research?","volume":"8","author":"Motulsky","year":"2021","journal-title":"Qual Psychol"},{"issue":"5","key":"zoi260477r19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1188\/14.ONF.545-547","article-title":"The use of triangulation in qualitative research.","volume":"41","author":"Carter","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"zoi260477r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074256","article-title":"Practical thematic analysis: a guide for multidisciplinary health services research teams engaging in qualitative analysis.","volume":"381","author":"Saunders","year":"2023","journal-title":"BMJ"},{"issue":"2","key":"zoi260477r21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jid.2020.11.029","article-title":"Research techniques made simple: an introduction to qualitative research.","volume":"141","author":"Bazen","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"3","key":"zoi260477r22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamasurg.2013.1048","article-title":"Expectations for weight loss and willingness to accept risk among patients seeking weight loss surgery.","volume":"148","author":"Wee","year":"2013","journal-title":"JAMA Surg"},{"key":"zoi260477r23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis.","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"issue":"24","key":"zoi260477r24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260477r26","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.68","article-title":"Relationship between diet\/exercise and pharmacotherapy to enhance the GLP-1 levels in type 2 diabetes.","volume":"2","author":"Fujiwara","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"zoi260477r28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s43856-024-00566-z","article-title":"Using large language models to assess public perceptions around glucagon-like peptide-1 receptor agonists on social media.","volume":"4","author":"Somani","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"9","key":"zoi260477r29","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US.","volume":"14","author":"Pearson","year":"2025","journal-title":"J Comp Eff Res"},{"key":"zoi260477r30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","article-title":"GLP-1 agonists: a review for emergency clinicians.","volume":"78","author":"Long","year":"2024","journal-title":"Am J Emerg Med"},{"key":"zoi260477r3","unstructured":"Obesity. ICD-11 for Mortality and Morbidity Statistics. Accessed January 23, 2026. https:\/\/icd.who.int\/browse\/2024-01\/mms\/en#149403041"},{"key":"zoi260477r16","unstructured":"The SAGE Encyclopedia of Social Science Research Methods: constant comparison. Sage. 2004. Accessed July 11, 2202. https:\/\/methods.sagepub.com\/reference\/the-sage-encyclopedia-of-social-science-research-methods\/n161.xml?"},{"key":"zoi260477r25","unstructured":"A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and\/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN). Clinicaltrials.gov identifier: NCT06047548. Last updated March 25, 2026. Accessed January 26, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06047548"},{"key":"zoi260477r27","unstructured":"WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults. World Health Organization. Accessed January 26, 2026. https:\/\/app.magicapp.org\/#\/guideline\/LrRxrL"},{"key":"zoi260477r31","unstructured":"Pratap, A. Looming GLP-1 drug patent expirations draw generics firms. Chemical & Engineering News. December 9, 2025. Accessed January 26, 2026. https:\/\/cen.acs.org\/pharmaceuticals\/Looming-GLP-1-drug-patent\/103\/web\/2025\/12"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849943\/de_vere_hunt_2026_oi_260477_1780001351.12403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:30:21Z","timestamp":1780673421000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.16951","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}